CTOs on the Move

BioSig Technologies

www.biosigtech.com

 
BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.biosigtech.com
  • 8441 Wayzata Blvd Ste 240
    Minneapolis, MN USA 55426
  • Phone: 763.999.7330

Executives

Name Title Contact Details

Similar Companies

Ontario Long Term Care Association

Ontario Long Term Care Association is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CleanCare Healthcare Division

CleanCare Healthcare Division is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Test Equipment Distributors

Test Equipment Distributors is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medcorp

Medcorp is a Springfield, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dimension Therapeutics

Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.